Clinical Trials Directory

Trials / Conditions / Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

21 registered clinical trials studyying Lung Squamous Cell Carcinoma — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingPeripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
NCT07392073
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine—
RecruitingJMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073
Shanghai JMT-Bio Inc.Phase 1
RecruitingA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726
Terremoto Biosciences Inc.Phase 1 / Phase 2
WithdrawnSTRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescima
NCT07038915
M.D. Anderson Cancer CenterPhase 2
RecruitingPhase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally
NCT06121505
Sichuan UniversityPhase 2
RecruitingMechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell
NCT06436040
Tang-Du Hospital—
UnknownA Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
NCT05782764
Xuzhou Medical UniversityPhase 4
RecruitingThe Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
NCT05778253
Second Xiangya Hospital of Central South University—
Active Not RecruitingPredictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
NCT07147361
Cancer Institute and Hospital, Chinese Academy of Medical Sciences—
UnknownTislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Car
NCT05024266
First Affiliated Hospital of Zhejiang UniversityPhase 2
Active Not RecruitingEfficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express
NCT04802876
SOLTI Breast Cancer Research GroupPhase 2
WithdrawnTesting of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous C
NCT04267913
SWOG Cancer Research NetworkPhase 2
UnknownIdentify Prognostic Biomarkers of Lung Cancer
NCT05010330
RenJi Hospital—
TerminatedStudy of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
NCT04152018
PfizerPhase 1
RecruitingCharacteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197
Cancer Institute and Hospital, Chinese Academy of Medical Sciences—
UnknownTo Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
NCT04132102
Shanghai Chest HospitalPhase 4
UnknownApatinib for Advanced Lung Squmamous Carcinoma
NCT03725423
Xuzhou Central HospitalPhase 4
UnknownAnti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
NCT02876978
CARsgen Therapeutics Co., Ltd.Phase 1
CompletedOral Rigosertib for Squamous Cell Carcinoma
NCT01807546
Traws Pharma, Inc.Phase 2
Active Not RecruitingVeliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small
NCT01386385
National Cancer Institute (NCI)Phase 1 / Phase 2
Active Not RecruitingCombination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage I
NCT00334815
National Cancer Institute (NCI)Phase 2